113 related articles for article (PubMed ID: 1830752)
21. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
[TBL] [Abstract][Full Text] [Related]
22. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
Lardy C; Rousselot C; Chavernac G; Depin JC; Guerrier D
Arzneimittelforschung; 1994 Nov; 44(11):1196-202. PubMed ID: 7848331
[TBL] [Abstract][Full Text] [Related]
23. Comparison of vascular and platelet thromboxane A2/prostaglandin H2 receptors in the pig.
Mihara S; Hara S; Ueda M; Ide M; Fujimoto M
Eur J Pharmacol; 1989 Feb; 160(3):313-21. PubMed ID: 2523812
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and thromboxane A2 antagonist activity of N-benzyltrimetoquinol analogues.
Harrold MW; Grajzl B; Shin YM; Romstedt KJ; Feller DR; Miller DD
J Med Chem; 1988 Aug; 31(8):1506-12. PubMed ID: 3397988
[TBL] [Abstract][Full Text] [Related]
25. Binding of a thromboxane A2/prostaglandin H2 agonist [3H]U46619 to washed human platelets.
Liel N; Mais DE; Halushka PV
Prostaglandins; 1987 Jun; 33(6):789-97. PubMed ID: 2959986
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist.
Ogletree ML; Harris DN; Schumacher WA; Webb ML; Misra RN
J Pharmacol Exp Ther; 1993 Feb; 264(2):570-8. PubMed ID: 8437108
[TBL] [Abstract][Full Text] [Related]
27. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
Okwu AK; Ullian ME; Halushka PV
J Pharmacol Exp Ther; 1992 Jul; 262(1):238-45. PubMed ID: 1378092
[TBL] [Abstract][Full Text] [Related]
28. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
Yin K; Halushka PV; Yan YT; Wong PY
J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
[TBL] [Abstract][Full Text] [Related]
29. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction.
Johnson GJ; Leis LA; Dunlop PC
J Clin Invest; 1993 Nov; 92(5):2469-79. PubMed ID: 8227362
[TBL] [Abstract][Full Text] [Related]
30. Syntheses and beta-adrenergic agonist and antiaggregatory properties of N-substituted trimetoquinol analogues.
Adejare A; Miller DD; Fedyna JS; Ahn CH; Feller DR
J Med Chem; 1986 Sep; 29(9):1603-9. PubMed ID: 2875182
[TBL] [Abstract][Full Text] [Related]
31. Thromboxane A2 accounts for bronchoconstriction but not for platelet sequestration and microvascular albumin exchanges induced by fMLP in the guinea pig lung.
Bureau MF; De Clerck F; Lefort J; Arreto CD; Vargaftig BB
J Pharmacol Exp Ther; 1992 Feb; 260(2):832-40. PubMed ID: 1738127
[TBL] [Abstract][Full Text] [Related]
32. Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate.
Karasawa A; Kawakage M; Shirakura S; Higo K; Kubo K; Ohshima E; Obase H
Arzneimittelforschung; 1991 Dec; 41(12):1230-6. PubMed ID: 1840011
[TBL] [Abstract][Full Text] [Related]
33. Regulation of thromboxane receptor activation in human platelets.
Murray R; FitzGerald GA
Proc Natl Acad Sci U S A; 1989 Jan; 86(1):124-8. PubMed ID: 2521385
[TBL] [Abstract][Full Text] [Related]
34. Antagonism of prostaglandin-mediated responses in platelets and vascular smooth muscle by 13-azaprostanoic acid analogs. Evidence for selective blockade of thromboxane A2 responses.
Huzoor-Akbar ; Mukhopadhyay A; Anderson KS; Navran SS; Romstedt K; Miller DD; Feller DR
Biochem Pharmacol; 1985 Mar; 34(5):641-7. PubMed ID: 3156599
[TBL] [Abstract][Full Text] [Related]
35. Platelet endoperoxide/thromboxane A2 (PGH2/TXA2) receptors in patients with myeloproliferative disorders.
Faul C; Renn W; Jaschonek K
Prostaglandins Leukot Essent Fatty Acids; 1991 Aug; 43(4):273-6. PubMed ID: 1835097
[TBL] [Abstract][Full Text] [Related]
36. The use of synthetic thromboxane A2 (TXA2-S) and a new class of thromboxane antagonists, indole-2-propanoic acids to characterize the thromboxane receptor.
Gillard JW; Morton HE; Fortin R; Yoakim C; Girard Y; Lord A; Ethier D; Leveille C; Letts G; Evans J
Prog Clin Biol Res; 1989; 301():579-83. PubMed ID: 2529557
[No Abstract] [Full Text] [Related]
37. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets.
Swann PG; Venton DL; Le Breton GC
FEBS Lett; 1989 Jan; 243(2):244-6. PubMed ID: 2537230
[TBL] [Abstract][Full Text] [Related]
38. Desensitisation of human platelets against stimulation by thromboxane mimics--reduction in receptor capacity and loss of functional response.
Thierauch KH; Gabriel D; Prior G; Schillinger E
Biomed Biochim Acta; 1988; 47(10-11):S75-8. PubMed ID: 2470362
[TBL] [Abstract][Full Text] [Related]
39. Blockade of thromboxane and the prevention of eicosanoid-induced sudden death in mice.
Darius H; Lefer AM
Proc Soc Exp Biol Med; 1985 Nov; 180(2):364-8. PubMed ID: 2996012
[TBL] [Abstract][Full Text] [Related]
40. Polymyxin B increases TXA2/PGH2 agonist and antagonist affinities in human platelet membranes.
Halushka PV; Boehm A; Mais DE
Eicosanoids; 1988; 1(1):41-4. PubMed ID: 2856171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
